A cellular model and attendant methodology wherein the cellular model expresses Alzheimer-like lesions or characteristics resulting from the consequences of the natural inhibitory effects of tryptamine on enzyme activity of aminoacyl-tRNA synthetase in human differentiated neuronal cells. Epithelial cells are segregated from neuroblast cells in a human neuroblast cell line, by either subjecting the neuroblast cell line to the inhibitory effects of tryptamine or alternately removing the neuroblast cells from the epithelial cells by utilization of a washing solution of tryp5in. The methodology for generation of the cellular models results in a plurality of distinct cell groupings each of which may be used for control cellular models or for analyses purposes, wherein the plurality of groupings of epithelial cells comprise a first grouping expressing differentiated neuron-axon phenotype, a second grouping characterized by the epithelial cells being untreated and unaffected by the inhibitory affects of tryptamine, and a third grouping characterized by an acute treatment with tryptamine subsequent to separation from the neuroblast cells. The effectiveness of the cellular model producing methodology is evaluated based on immunogold electron, immunofluorescent and immunoperoxidase light microscopic identification of the Alzheimer's-like indicators including intra- and extracellular neurofibrillary tangles in the differentiated neuronal human cells and extracellular plaques.
A TRYPTAMINE TREATED, HUMAN DIFFERENTIATED, NEURONAL ALZHEIMER-LIKE CELL AND ATTENDANT METHODS OF CELL MODELING